BCA
RIGL icon

Berman Capital Advisors’s Rigel Pharmaceuticals RIGL Stock Holding History

Berman Capital Advisors’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		$1K Sell
28
-6
-18% -$236 ﹤0.01% 1943
2021
Q2 		$1K Buy
34
+6
+21% +$227 ﹤0.01% 1797
2021
Q1 		$0 Hold
28
– – ﹤0.01% 1875
2020
Q4 		$0 Hold
28
– – ﹤0.01% 1805
2020
Q3 		$0 Hold
28
– – ﹤0.01% 1748
2020
Q2 		$0 Hold
28
– – ﹤0.01% 1783
2020
Q1 		$0 Hold
28
– – ﹤0.01% 1632
2019
Q4 		$0 Hold
28
– – ﹤0.01% 1531
2019
Q3 		$0 Hold
28
– – ﹤0.01% 1554
2019
Q2 		$0 Hold
28
– – ﹤0.01% 1557
2019
Q1 		$0 Hold
28
– – ﹤0.01% 1456
2018
Q4 		$0 Buy
+28
New +$790 ﹤0.01% 1238

Other funds holding RIGL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TA
Tamarack Advisers Carlsbad, California $2.12M AUM 58.09% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Berman Capital Advisors's RIGL Position: Q3 2021 in Review

Berman Capital Advisors reduced its Rigel Pharmaceuticals (RIGL) stake by 18% in Q3 2021, selling an estimated $236 and leaving 28 shares worth $1K. The position accounts for ﹤0.01% of the portfolio, ranked #1943.

Berman Capital Advisors first reported a position in RIGL in Q4 2018 and has held it in 12 quarters since. 163 funds tracked by Wall St. Rank hold RIGL as of Q3 2021.

  • Berman Capital Advisors held 28 shares of Rigel Pharmaceuticals worth $1K as of Q3 2021.
  • Berman Capital Advisors sold 6 Rigel Pharmaceuticals shares in Q3 2021, an estimated $236.
  • Rigel Pharmaceuticals made up ﹤0.01% of Berman Capital Advisors's portfolio in Q3 2021, its #1943 holding.
  • Berman Capital Advisors first reported a position in Rigel Pharmaceuticals in Q4 2018 and has held it in 12 quarters since.
  • 163 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q3 2021.

Based on Berman Capital Advisors's 13F filing for Q3 2021, filed 7 Oct 2021.